The prognosis of gastric cancer patients with marginally elevated carcinoembryonic antigen (CEA) values after D2 radical gastrectomy

2013 ◽  
Vol 107 (6) ◽  
pp. 641-645 ◽  
Author(s):  
Shi Chen ◽  
Xing-Yu Feng ◽  
Yuan-Fang Li ◽  
Bai-Wei Zhao ◽  
Zhi-Wei Zhou ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Carcinoembryonic Antigen ◽  
Cancer Patients ◽  
Radical Gastrectomy ◽  
Gastric Cancer Patients

PILGRIM: Phase III clinical trial in evaluating the role of hyperthermic intraperitoneal chemotherapy for locally advanced gastric cancer patients after radical gastrectomy with D2 lymphadenectomy(HIPEC-01).

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 4538-4538
Author(s):  
Shu-zhong Cui ◽  
Han Liang ◽  
Yong Li ◽  
Yanbing Zhou ◽  
Kaixiong Tao ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Locally Advanced ◽  
Control Group ◽  
Radical Gastrectomy ◽  
Node Dissection ◽  
D2 Lymph Node Dissection ◽  
Locally Advanced Gastric Cancer ◽  
Gastric Cancer Patients

4538 Background: Gastric cancer remains the 3rd leading cancer related death worldwide due to early disease recurrence. We hypothesize that hyperthermic intraperitoneal chemotherapy (HIPEC) may effectively prevent local regional recurrence for locally advanced gastric cancer patients who received curative intent surgery. Methods: Pathology proven gastric cancer patients with clinical T3/T4NxM0 disease are eligible for the study and will be randomized to either control group, who will receive standard radical gastrectomy and D2 lymph node dissection or HIPEC group, who will receive the same surgery and HIPEC with paclitaxel x 2 within the first week after surgery. All patients will receive either XELOX or SOX adjuvant chemotherapy. The primary end point is overall survival. Results: 648 patients from 16 high volume gastric medical centers were enrolled between May, 2015 and March, 2019. 331 and 317 patients were randomized to control and HIPEC groups respectively. The median follow-up time is 12.1 months. The common grade 3/4 toxicities ( > 5%) in control and HIPEC groups are anemia 6% vs. 4.1%, intraabdominal infection 5.4% vs. 3.8%, pneumonia 9.7% vs. 9.8%, fever 10.6% vs. 11.4% and hypoalbunemia 15.1% vs. 16.7% respectively. All three perioperative death (within 30 days after surgery) occurred in control group. One patient died from duodenum stump leak which led to multiple organ failure. One patient died from anastomotic led to intraabdominal infection and shock. The 3rd death was suicide caused by severe depression. At the time of this report, the number of event has not reached for final efficacy analysis. Conclusions: It is safe to administer HIPEC to patients received radical gastrectomy with D2 lymph node dissection within one week of surgery. The primary analysis will be expected in one year. Clinical trial information: NCT02356276 .

Safety of laparoscopic radical gastrectomy in gastric cancer patients with liver cirrhosis

2017 ◽  
Vol 31 (10) ◽  
pp. 3898-3904 ◽  
Author(s):  
Dong Jin Kim ◽  
Cho Hyun Park ◽  
Wook Kim ◽  
Hyung Min Jin ◽  
Jin Jo Kim ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Liver Cirrhosis ◽  
Cancer Patients ◽  
Radical Gastrectomy ◽  
Gastric Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document